SIH Partners’s Blueprint Medicines BPMC Stock Holding History

SIH Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,027	Closed	-$356K	–	192
2025 Q1	$356K	Buy	+4,027	New	+$393K	0.01%	182

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SIH Partners's BPMC Position: Q2 2025 in Review

SIH Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 4,027 shares — an estimated $356K sold.

SIH Partners first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $356K in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

SIH Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 4,027 Blueprint Medicines shares in Q2 2025, an estimated $356K.
SIH Partners first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
SIH Partners's Blueprint Medicines position peaked at $356K in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.